Smart R C, Mills K J, Hansen L A, Conney A H
Department of Toxicology, North Carolina State University, Raleigh 27695-7633.
Cancer Res. 1989 Aug 15;49(16):4455-8.
sn-1,2-Didecanoylglycerol, a synthetic lipid second messenger and model diacylglycerol, was evaluated as a complete skin tumor promoter in CD-1 mice. In addition, sn-1,2-dioctanoylglycerol, sn-1,2-didecanoylglycerol, the second stage tumor promoter mezerein, and the complete tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) were examined for their ability to stimulate epidermal protein kinase C activity in vitro. All four compounds stimulated epidermal protein kinase C activity utilizing lysine-rich histone as the phosphate acceptor substrate. sn-1,2-Dioctanoylglycerol and sn-1,2-didecanoylglycerol stimulated epidermal protein kinase C activity to a maximum velocity similar to that obtained when the enzyme was stimulated with TPA; however, about 1000 times greater concentration of the sn-1,2-diacylglycerols was required. sn-1,2-Didecanoylglycerol was evaluated as a complete skin tumor promoter in CD-1 mice utilizing a dosing regimen demonstrated to produce epidermal hyperplasia. Mice were initiated with 200 nmol 7,12-dimethylbenz[a]anthracene. One week later the mice received twice daily topical applications of 1 nmol TPA, 2 mumol sn-1,2-didecanoylglycerol or 5 mumol sn-1,2-didecanoylglycerol, 5 days/week. Additional initiated mice received twice weekly topical applications of 2 or 5 nmol TPA. Initiated mice treated with 5 nmol TPA twice weekly or with 1 nmol TPA twice daily for 5 days/week (cumulative weekly doses of 10 nmol TPA) responded similarly, based on the tumor incidence and the average number of tumors per mouse. Initiated mice treated with 2 or 5 mumol sn-1,2-didecanoylglycerol twice daily developed tumors in a dose-dependent manner. Initiated mice treated with 5 mumol sn-1,2-didecanoylglycerol twice daily developed many tumors, and at 20 weeks there was a 74% tumor incidence and an average of 6.0 tumors/mouse. At 20 weeks, 24% of the initiated mice treated with 2 mumol sn-1,2-didecanoylglycerol twice daily developed tumors, with an average of 1.1 tumors/mouse. Mice which were not initiated but treated twice daily with 5 mumol sn-1,2-didecanoylglycerol for 20 weeks did not develop any tumors. These data demonstrate that the representative synthetic lipid second messenger sn-1,2-didecanoylglycerol, like TPA, is a complete tumor promoter in DMBA-initiated mouse skin.
sn-1,2-二癸酰甘油是一种合成脂质第二信使及二酰基甘油模型,在CD-1小鼠中被评估为一种完全性皮肤肿瘤促进剂。此外,还检测了sn-1,2-二辛酰甘油、sn-1,2-二癸酰甘油、第二阶段肿瘤促进剂芫花酯素以及完全性肿瘤促进剂12-O-十四酰佛波醇-13-乙酸酯(TPA)在体外刺激表皮蛋白激酶C活性的能力。所有这四种化合物都利用富含赖氨酸的组蛋白作为磷酸受体底物来刺激表皮蛋白激酶C活性。sn-1,2-二辛酰甘油和sn-1,2-二癸酰甘油刺激表皮蛋白激酶C活性达到的最大速度与用TPA刺激该酶时所获得的相似;然而,sn-1,2-二酰基甘油所需的浓度大约要高1000倍。利用已证明能产生表皮增生的给药方案,在CD-1小鼠中评估了sn-1,2-二癸酰甘油作为一种完全性皮肤肿瘤促进剂的作用。用200 nmol 7,12-二甲基苯并[a]蒽启动小鼠。一周后,小鼠每周5天每天接受两次局部涂抹1 nmol TPA、2 μmol sn-1,2-二癸酰甘油或5 μmol sn-1,2-二癸酰甘油。另外一些已启动的小鼠每周接受两次局部涂抹2或5 nmol TPA。基于肿瘤发生率和每只小鼠的平均肿瘤数,每周两次用5 nmol TPA处理或每周5天每天两次用1 nmol TPA处理(TPA的累积每周剂量为10 nmol)的已启动小鼠反应相似。每天两次用2或5 μmol sn-1,2-二癸酰甘油处理的已启动小鼠以剂量依赖方式发生肿瘤。每天两次用5 μmol sn-1,2-二癸酰甘油处理已启动小鼠发生了许多肿瘤,在20周时肿瘤发生率为74%且平均每只小鼠有6.0个肿瘤。在20周时,每天两次用2 μmol sn-1,2-二癸酰甘油处理的已启动小鼠中有24%发生肿瘤,平均每只小鼠有1.1个肿瘤。未启动但每天两次用5 μmol sn-1,2-二癸酰甘油处理20周的小鼠未发生任何肿瘤。这些数据表明,代表性的合成脂质第二信使sn-1,2-二癸酰甘油与TPA一样,是DMBA启动的小鼠皮肤中的一种完全性肿瘤促进剂。